{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T11:19:09Z","timestamp":1768562349790,"version":"3.49.0"},"reference-count":52,"publisher":"Oxford University Press (OUP)","issue":"S3","license":[{"start":{"date-parts":[[2004,6,3]],"date-time":"2004-06-03T00:00:00Z","timestamp":1086220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2004,6,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Learning Objectives<\/jats:title>\n                  <jats:p>After completing this course, the reader will be able to:<\/jats:p>\n                  <jats:p>Discuss patterns of resistance to endocrine therapy for breast cancer. Relate differences in resistance patterns in early and advanced disease settings. Identify potential treatment strategies to overcome resistance and\/or restore endocrine therapy efficacy.<\/jats:p>\n                  <jats:p>Access and take the CME test online and receive 1 hour of AMA PRA category 1 credit at CME.TheOncologist.com<\/jats:p>\n                  <jats:p>Endocrine therapy is the most effective systemic treatment for patients with hormone-receptor-positive (HR+) breast cancer. Unfortunately, efficacy is often limited by the onset of resistance, which is almost inevitable for patients with advanced disease. Several patterns of endocrine resistance are recognizable clinically, including: A) tumors that are inherently insensitive to all attempts at estrogen receptor (ER) targeting despite expression of ER (pan-endocrine therapy resistance); B) tumors that are estrogen dependent but resistant to one or more specific endocrine therapies (agent-selective resistance); and C) tumors that initially respond but subsequently progress (acquired resistance). Current insights into the molecular basis for these resistance patterns are rudimentary, but are most clearly illuminated by investigations that focus on the crosstalk between the ErbB or HER peptide growth factor family and the ER. The data are sufficiently compelling to be addressed by ongoing clinical trials that examine combinations of endocrine agents and either trastuzumab (Herceptin\u00ae; Genentech, Inc.; South San Francisco, CA) or ErbB-specific tyrosine kinase (TK) inhibitors. Preliminary data from a small \u201cproof of concept\u201d phase II study of letrozole (Femara\u00ae; Novartis Pharmaceuticals Corporation; East Hanover, NJ) and trastuzumab demonstrated durable responses despite tamoxifen (Nolvadex\u00ae; AstraZeneca Pharmaceuticals; Wilmington, DE) resistance. Efficacy was variable, however, despite the selection of patients on the basis of ER and ErbB-2 coexpression. Complicating matters further, resistance often occurs in the absence of any evidence for ErbB TK family member expression. In the absence of a clear target, common downstream signal transduction proteins that are known to intersect with the ER pathway can be inhibited to address resistance, including G proteins with farnesyltransferase inhibitors and molecular target of rapamycin (mTOR) with rapamycin analogues. With a number of phase III clinical trials now under way, major advances in the endocrine treatment of advanced disease are possible.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.9-suppl_3-20","type":"journal-article","created":{"date-parts":[[2004,8,24]],"date-time":"2004-08-24T21:38:39Z","timestamp":1093383519000},"page":"20-26","source":"Crossref","is-referenced-by-count":63,"title":["Overcoming Endocrine Therapy Resistance by Signal Transduction Inhibition"],"prefix":"10.1093","volume":"9","author":[{"given":"Matthew","family":"Ellis","sequence":"first","affiliation":[{"name":"Siteman Cancer Center, Washington University, St. Louis, Missouri, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2004,6,3]]},"reference":[{"key":"2021122209453350400_R1","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.1200\/JCO.2001.19.10.2596","article-title":"Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group","volume":"19","author":"Mouridsen","year":"2001","journal-title":"J Clin Oncol"},{"key":"2021122209453350400_R2","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1200\/JCO.2000.18.22.3758","article-title":"Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial","volume":"18","author":"Nabholtz","year":"2000","journal-title":"J Clin Oncol"},{"key":"2021122209453350400_R3","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1200\/JCO.1998.16.2.453","article-title":"Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate","volume":"16","author":"Dombernowsky","year":"1998","journal-title":"J Clin Oncol"},{"key":"2021122209453350400_R4","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1200\/JCO.2000.18.7.1399","article-title":"Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group","volume":"18","author":"Kaufmann","year":"2000","journal-title":"J Clin Oncol"},{"key":"2021122209453350400_R5","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1200\/JCO.1996.14.7.2000","article-title":"Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group","volume":"14","author":"Buzdar","year":"1996","journal-title":"J Clin Oncol"},{"key":"2021122209453350400_R6","first-page":"1451","article-title":"Early Breast Cancer Trialists' Collaborative Group","volume":"351","author":"Tamoxifen for early breast cancer: an overview of the randomised trials","year":"1998","journal-title":"Lancet"},{"key":"2021122209453350400_R7","first-page":"6523","article-title":"Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1\/2 expression status","volume":"63","author":"Ellis","year":"2003","journal-title":"Cancer Res"},{"key":"2021122209453350400_R8","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/35052073","article-title":"Untangling the ErbB signalling network","volume":"2","author":"Yarden","year":"2001","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2021122209453350400_R9","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1200\/JCO.2002.09.094","article-title":"Evaluation of HER-2\/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens","volume":"20","author":"Press","year":"2002","journal-title":"J Clin Oncol"},{"key":"2021122209453350400_R10","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/jnci\/84.16.1279","article-title":"Correlation of HER-2\/neu amplification with expression and with other prognostic factors in 1103 breast cancers","volume":"84","author":"Ciocca","year":"1992","journal-title":"J Natl Cancer Inst"},{"key":"2021122209453350400_R11","first-page":"1344","article-title":"Hyperactivation of MAPK induces loss of ERalpha expression in breast cancer cells","volume":"15","author":"Oh","year":"2001","journal-title":"Mol Endocrinol"},{"key":"2021122209453350400_R12","first-page":"44a","article-title":"Estrogen receptor (ER) status does not predict benefit to trastuzumab (Herceptin): a review of the Herceptin clinical trials experience","volume":"20","author":"Bolton","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"2021122209453350400_R13","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/BF01961241","article-title":"Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2\/neu","volume":"24","author":"Benz","year":"1993","journal-title":"Breast Cancer Res Treat"},{"key":"2021122209453350400_R14","first-page":"2435","article-title":"HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells","volume":"10","author":"Pietras","year":"1995","journal-title":"Oncogene"},{"key":"2021122209453350400_R15","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/BF00665783","article-title":"MCF-7 breast cancer cells overexpressing transfected c-erbB-2 have an in vitro growth advantage in estrogen-depleted conditions and reduced estrogen-dependence and tamoxifen-sensitivity in vivo","volume":"34","author":"Liu","year":"1995","journal-title":"Breast Cancer Res Treat"},{"key":"2021122209453350400_R16","first-page":"1643","article-title":"Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer","volume":"3","author":"Newby","year":"1997","journal-title":"Clin Cancer Res"},{"key":"2021122209453350400_R17","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1677\/erc.0.0080175","article-title":"Modulation of epidermal growth factor receptor in endocrine-resistant, oestrogen receptor-positive breast cancer","volume":"8","author":"Nicholson","year":"2001","journal-title":"Endocr Relat Cancer"},{"key":"2021122209453350400_R18","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1749-6632.2002.tb04101.x","article-title":"Modulation of epidermal growth factor receptor in endocrine-resistant, estrogen-receptor-positive breast cancer","volume":"963","author":"Nicholson","year":"2002","journal-title":"Ann N Y Acad Sci"},{"key":"2021122209453350400_R19","first-page":"4436s","article-title":"Inhibition of erbB receptor (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancer","volume":"7","author":"Kurokawa","year":"2001","journal-title":"Clin Cancer Res"},{"key":"2021122209453350400_R20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1023\/A:1005798224288","article-title":"Enhanced anti-proliferative activity of the combination of tamoxifen plus HER-2-neu antibody","volume":"42","author":"Witters","year":"1997","journal-title":"Breast Cancer Res Treat"},{"key":"2021122209453350400_R21","first-page":"1163","article-title":"Restoration of estrogen responsiveness by blocking the HER-2\/neu pathway","volume":"9","author":"Witters","year":"2002","journal-title":"Oncol Rep"},{"key":"2021122209453350400_R22","first-page":"511S","article-title":"ErbB (HER) receptors can abrogate antiestrogen action in human breast cancer by multiple signaling mechanisms","volume":"9","author":"Kurokawa","year":"2003","journal-title":"Clin Cancer Res"},{"key":"2021122209453350400_R23","first-page":"5887","article-title":"Inhibition of HER2\/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells","volume":"60","author":"Kurokawa","year":"2000","journal-title":"Cancer Res"},{"key":"2021122209453350400_R24","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1677\/erc.0.0080191","article-title":"Overexpression of HER-2 as a resistance mechanism to hormonal therapy for breast cancer","volume":"8","author":"Dowsett","year":"2001","journal-title":"Endocr Relat Cancer"},{"key":"2021122209453350400_R25","first-page":"3","article-title":"Serum HER-2\/neu conversion to positive at the time of cancer progression in metastatic breast patients treated with letrozole vs. tamoxifen","volume":"22","author":"Lipton","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"2021122209453350400_R26","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1093\/jnci\/88.20.1456","article-title":"Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers","volume":"88","author":"Hayes","year":"1996","journal-title":"J Natl Cancer Inst"},{"key":"2021122209453350400_R27","first-page":"11","article-title":"A meta-analysis of the interaction between HER2 expression and response to endocrine treatment in advanced breast cancer","volume":"2","author":"Laurentis","year":"2000","journal-title":"Biological Therapy of Cancer"},{"key":"2021122209453350400_R28","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1200\/JCO.2003.09.098","article-title":"Serum HER-2\/neu and response to the aromatase inhibitor letrozole versus tamoxifen","volume":"21","author":"Lipton","year":"2003","journal-title":"J Clin Oncol"},{"key":"2021122209453350400_R29","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1053\/ejso.2000.1078","article-title":"Does c-erbB2\/HER2 overexpression predict adjuvant tamoxifen failure in patients with early breast cancer?","volume":"27","author":"Hu","year":"2001","journal-title":"Eur J Surg Oncol"},{"key":"2021122209453350400_R30","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1200\/JCO.2003.10.133","article-title":"Her-2\/neu overexpression and response to oophorectomy plus tamoxifen adjuvant therapy in estrogen receptor-positive premenopausal women with operable breast cancer","volume":"21","author":"Love","year":"2003","journal-title":"J Clin Oncol"},{"key":"2021122209453350400_R31","doi-asserted-by":"crossref","first-page":"3808","DOI":"10.1200\/JCO.2001.19.18.3808","article-title":"Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and\/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial","volume":"19","author":"Ellis","year":"2001","journal-title":"J Clin Oncol"},{"key":"2021122209453350400_R32","first-page":"447S","article-title":"Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response","volume":"9","author":"Schiff","year":"2003","journal-title":"Clin Cancer Res"},{"key":"2021122209453350400_R33","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1093\/jnci\/95.5.353","article-title":"Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2\/neu in tamoxifen resistance in breast cancer","volume":"95","author":"Osborne","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"2021122209453350400_R34","first-page":"1259","article-title":"Expression analysis of estrogen receptor alpha coregulators in breast carcinoma: evidence that NCOR1 expression is predictive of the response to tamoxifen","volume":"9","author":"Girault","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"suppl 1","key":"2021122209453350400_R35","first-page":"S106","article-title":"A phase II trial of letrozole and trastuzumab for ER and\/or PgR and HER2 positive metastatic breast cancer","volume":"82","author":"Wong","year":"2003","journal-title":"Breast Cancer Res Treat"},{"key":"2021122209453350400_R36","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1200\/JCO.2002.20.6.1467","article-title":"Elevated serum Her-2\/neu level predicts decreased response to hormone therapy in metastatic breast cancer","volume":"20","author":"Lipton","year":"2002","journal-title":"J Clin Oncol"},{"key":"2021122209453350400_R37","doi-asserted-by":"crossref","first-page":"9042","DOI":"10.1073\/pnas.160016897","article-title":"Down-regulation of p21WAF1\/CIP1 or p27Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells","volume":"97","author":"Cariou","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"2021122209453350400_R38","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1677\/erc.0.0080227","article-title":"Farnesyl transferase inhibitors\u2014a novel therapy for breast cancer","volume":"8","author":"Johnston","year":"2001","journal-title":"Endocr Relat Cancer"},{"key":"2021122209453350400_R39","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1126\/science.8316834","article-title":"Benzodiazepine peptidomimetics: potent inhibitors of Ras farnesylation in animal cells","volume":"260","author":"James","year":"1993","journal-title":"Science"},{"key":"2021122209453350400_R40","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1128\/MCB.19.3.1831","article-title":"Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB","volume":"19","author":"Du","year":"1999","journal-title":"Mol Cell Biol"},{"key":"2021122209453350400_R41","doi-asserted-by":"crossref","first-page":"30451","DOI":"10.1074\/jbc.M003469200","article-title":"Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules","volume":"275","author":"Ashar","year":"2000","journal-title":"J Biol Chem"},{"key":"2021122209453350400_R42","first-page":"S71","article-title":"Endocrine therapy combined with the farnesyl transferase inhibitor (FTI) R115777 produces enhanced tumor growth inhibition in hormone-sensitive MCF-7 human breast cancer xenografts in vivo","volume":"76","author":"Johnston","year":"2002","journal-title":"Breast Cancer Res Treat"},{"key":"2021122209453350400_R43","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/ijc.11263","article-title":"Additive effects of tamoxifen and the farnesyl transferase inhibitor FTI-277 on inhibition of MCF-7 breast cancer cell-cycle progression","volume":"106","author":"Doisneau-Sixou","year":"2003","journal-title":"Int J Cancer"},{"key":"2021122209453350400_R44","doi-asserted-by":"crossref","first-page":"9817","DOI":"10.1074\/jbc.M010840200","article-title":"Phosphatidylinositol 3-kinase\/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance","volume":"276","author":"Campbell","year":"2001","journal-title":"J Biol Chem"},{"key":"2021122209453350400_R45","first-page":"1249","article-title":"CCI-779 Wyeth","volume":"3","author":"Elit","year":"2002","journal-title":"Curr Opin Investig Drugs"},{"key":"2021122209453350400_R46","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1677\/erc.0.0080249","article-title":"mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer","volume":"8","author":"Yu","year":"2001","journal-title":"Endocr Relat Cancer"},{"key":"2021122209453350400_R47","first-page":"2887","article-title":"Pharmacodynamic evaluation of CCI-779, an inhibitor of mTOR, in cancer patients","volume":"9","author":"Peralba","year":"2003","journal-title":"Clin Cancer Res"},{"key":"2021122209453350400_R48","doi-asserted-by":"crossref","first-page":"126","DOI":"10.3816\/CBC.2003.n.018","article-title":"Mammalian target of rapamycin: a new molecular target for breast cancer","volume":"4","author":"Mita","year":"2003","journal-title":"Clin Breast Cancer"},{"key":"2021122209453350400_R49","first-page":"3","article-title":"Predictive value of p27KIP1 expression in premenopausal women with early-stage hormone receptor-positive breast cancer","volume":"22","author":"Filipits","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"2021122209453350400_R50","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1038\/nm762","article-title":"Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB\/Akt-mediated phosphorylation in breast cancer","volume":"8","author":"Viglietto","year":"2002","journal-title":"Nat Med"},{"key":"2021122209453350400_R51","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1038\/nm1002-1076","article-title":"Breast cancer banishes p27 from nucleus","volume":"8","author":"Blain","year":"2002","journal-title":"Nat Med"},{"key":"2021122209453350400_R52","doi-asserted-by":"crossref","first-page":"8418","DOI":"10.1073\/pnas.0932692100","article-title":"Repeated observation of breast tumor subtypes in independent gene expression data sets","volume":"100","author":"Sorlie","year":"2003","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.9-suppl_3-20","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.9-suppl_3-20","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/9\/S3\/20\/41844235\/oncolo_9_s3_20.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/9\/S3\/20\/41844235\/oncolo_9_s3_20.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T17:19:32Z","timestamp":1640193572000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/9\/S3\/20\/6387598"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,6,3]]},"references-count":52,"journal-issue":{"issue":"S3","published-online":{"date-parts":[[2004,6,3]]},"published-print":{"date-parts":[[2004,6,3]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.9-suppl_3-20","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2004,6,3]]},"published":{"date-parts":[[2004,6,3]]}}}